Encision (ECIA) AI Stock Analysis

12 Followers

Encision

(Other OTC:ECIA)

Select Model

Rating:42Neutral

Price Target:$0.03▲(123.08% Upside)

Action:upgraded

Date:11/07/26

The score is primarily held down by weak financial performance—declining revenue, widening losses, and negative operating/free cash flow alongside rising leverage. Technicals add some support from a short-term rebound (price above the 20-day average and RSI elevated), but the longer-term trend remains bearish with price below key longer moving averages and a negative MACD. Valuation is also constrained by ongoing losses (negative P/E) and no dividend yield provided.

Positive Factors

Focused AEM medical-device platformThe AEM platform gives Encision a clearly defined medical-device focus addressing a specific safety issue in laparoscopic surgery. Its use in instruments and related components also provides a coherent basis for product sales and potential commercial arrangements over the medium term.

Negative Factors

Declining revenue and widening lossesPersistent revenue contraction is weakening the scale available to support Encision’s operating structure, while widening losses show that current costs are not covered by sales. Unless revenue returns to growth or expenses are reduced, profitability and the company’s ability to fund development remain structurally constrained.

Encision (ECIA) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $221.12K
Dividend Yield: ―
Average Volume (3M): 13.40K
Price to Earnings (P/E): -13.1
Beta (1Y): 26.75
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 23
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

Encision Business Overview & Revenue Model

Company Description

Encision Inc. (ECIA), established in 1991 and headquartered in Boulder, Colorado, operates as a medical device firm specializing in the development, manufacturing, and commercialization of proprietary surgical instruments for the U.S. market. The com...

How the Company Makes Money

Encision’s primary revenue source was the sale of medical device products incorporating its Active Electrode Monitoring (AEM) technology, including AEM-enabled laparoscopic instruments and associated components used in electrosurgery. Beyond product...

Encision Financial Statement Overview

Summary

Financial statements indicate elevated risk: revenue has been declining (latest year down ~8%), losses widened (net margin ~-12% with deeply negative ROE), and both operating cash flow and free cash flow are negative. Gross margin remains solid (~47%), but current operating costs and cash burn outweigh that strength, while leverage has risen (debt ~1.19x equity).

Income Statement

28Negative

Balance Sheet

40Negative

Cash Flow

25Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Jun 2025	Jun 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	2.39M	5.78M	6.56M	6.59M	7.35M	7.67M
Gross Profit	1.12M	2.71M	3.51M	3.14M	4.03M	3.79M
EBITDA	53.67K	-542.60K	-95.08K	-544.20K	-217.51K	55.10K
Net Income	-16.94K	-719.08K	-220.20K	-691.78K	-366.00K	463.34K
Balance Sheet
Total Assets	3.45M	3.70M	3.67M	3.81M	4.13M	4.79M
Cash, Cash Equivalents and Short-Term Investments	275.43K	245.11K	257.43K	42.51K	189.00K	950.00K
Total Debt	1.42M	1.70M	1.31M	1.33M	1.08M	1.15M
Total Liabilities	1.96M	2.27M	2.02M	1.98M	1.64M	2.05M
Stockholders Equity	1.50M	1.43M	1.65M	1.83M	2.50M	2.75M
Cash Flow
Free Cash Flow	29.69K	-427.64K	-134.97K	107.57K	-1.04M	-480.00K
Operating Cash Flow	29.69K	-384.42K	-54.95K	144.39K	-861.00K	-444.00K
Investing Cash Flow	-4,712	-45.62K	-80.03K	-36.82K	-183.00K	-36.00K
Financing Cash Flow	5,342	417.72K	349.90K	-254.02K	284.00K	-44.00K

Encision Technical Analysis

Technical Analysis SentimentNegative

Last Price0.01

Price Trends

50DMA0.02Negative

100DMA0.06Negative

200DMA0.11Negative

Market Momentum

MACD-0.00Negative

RSI41.91Neutral

STOCH-3.33Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ECIA, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 41.91 is Neutral, neither overbought nor oversold. The STOCH value of -3.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ECIA.

Encision Risk Analysis

Encision disclosed 14 risk factors in its most recent earnings report. Encision reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Encision Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

ECIA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WOK	43Neutral	$5.58M	-0.01	-18.55%	―	―	―
LUCY	42Neutral	$7.03M	-0.65	-102.66%	―	56.89%	52.61%
ECIA	42Neutral	$221.12K	-13.10	-1.15%	―	―	―
GCTK	38Underperform	$284.19K	-0.00	-2135.52%	―	―	99.51%

* Healthcare Sector Average

Performance Comparison

ECIA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
ECIA	Encision Inc.	0.01	-0.23	-94.58%
GCTK	Glucotrack, Inc.	0.22	-155.78	-99.86%
LUCY	Innovative Eyewear, Inc.	0.81	-0.80	-49.81%
WOK	WORK Medical Technology Group LTD	1.20	-40898.80	-100.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026

Encision AI Stock Analysis